Articles citing this paper
Funding therapies for rare diseases: an ethical dilemma with a potential solution
Colman Taylor A B C D , Stephen Jan A B and Kelly Thompson A B
+ Author Affiliations
- Author Affiliations
A The George Institute for Global Health, PO Box M201, Missenden Road, Camperdown, NSW 2050, Australia. Email: sjan@georgeinstitute.org.au; kthompson@georgeinstitute.org.au
B Sydney Medical School, The University of Sydney, Edward Ford Building A27, The University of Sydney, NSW 2006, Australia.
C Optum, Level 1, 370 Norton Street, Lilyfield, NSW 2040, Australia.
D Corresponding author. Email: ctaylor@georgeinstitute.org.au
Australian Health Review 42(1) 117-119 https://doi.org/10.1071/AH16194
Submitted: 2 September 2016 Accepted: 9 December 2016 Published: 16 February 2017
12 articles found in Crossref database.
Assessing the impact of single or short-term administration on a therapy’s cost-effectiveness: a hypothetical disease-agnostic model
Klimchak Alexa C.,
Sedita Lauren E.,
Gooch Katherine L., Malone Daniel C.
Journal of Medical Economics. 2023 26(1). p.594
Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System
Yoo Seung-Lai,
Kim Dae-Jung,
Lee Seung-Mi,
Kang Won-Gu,
Kim Sang-Yoon,
Lee Jong, Suh Dong-Churl
International Journal of Environmental Research and Public Health. 2019 16(2). p.288
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis
Rubin Jaime L.,
Lopez Andrea,
Booth Jason,
Gunther Penilla, Jena Anupam B.
Journal of Medical Economics. 2022 25(1). p.783
Handbook of Bioethical Decisions. Volume I (2023)
Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review
Kacetl Jaroslav,
Marešová Petra,
Maskuriy Raihan, Selamat Ali
Risk Management and Healthcare Policy. 2020 Volume 13 p.2125
International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility
Jung Jae Ho,
Kim Dae Jung,
Suh Kangho,
You Jaeeun,
Lee Je Ho,
Joung Kyung In, Suh Dong Churl
International Journal of Environmental Research and Public Health. 2021 18(2). p.670
A systematic review of moral reasons on orphan drug reimbursement
Zimmermann Bettina M.,
Eichinger Johanna, Baumgartner Matthias R.
Orphanet Journal of Rare Diseases. 2021 16(1).
HTA decision-making for drugs for rare diseases: comparison of processes across countries
Stafinski Tania,
Glennie Judith,
Young Andrea, Menon Devidas
Orphanet Journal of Rare Diseases. 2022 17(1).
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
Klimchak Alexa C.,
Sedita Lauren E.,
Rodino-Klapac Louise R.,
Mendell Jerry R.,
McDonald Craig M.,
Gooch Katherine L., Malone Daniel C.
Journal of Market Access & Health Policy. 2023 11(1).
Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy
Vargas Constanza,
Addo Rebecca,
Lewandowska Milena,
Haywood Philip,
De Abreu Lourenco Richard, Goodall Stephen
Applied Health Economics and Health Policy. 2024 22(1). p.73
Strategies of Screening for Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy
Moiseev Sergey,
Karovaikina Ekaterina,
Moiseev Alexey,
Bulanov Nikolai, Fomin Victor
Mayo Clinic Proceedings. 2019 94(8). p.1644
Effect of the copayment reduction system on accessibility to orphan drugs in South Korea
Hwang Se-Eun,
Kim Minyoung,
Hong Youngjun,
Lee Dongyun,
Kim Taehyang,
Park Jihee,
Bae Junkyu, Lee Jong Hyuk
Expert Review of Pharmacoeconomics & Outcomes Research. 2023 23(5). p.519
